Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity
| Autor: | M Suoniemi, Florian Deisenhammer, Anna Fogdell-Hahn, Uroš Rot, Jan Hillert, Ajith Sominanda |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male Lung Neoplasms Multiple Sclerosis Adolescent In Vitro Techniques Antibodies 03 medical and health sciences Age Distribution 0302 clinical medicine Neutralization Tests Seroepidemiologic Studies Cell Line Tumor medicine Humans Immunologic Factors Seroprevalence 030212 general & internal medicine Clinical efficacy Neutralizing antibody Aged biology Interferon beta business.industry Multiple sclerosis Immunogenicity Interferon-beta Middle Aged medicine.disease Virology Titer Neurology Immunology biology.protein Female Neurology (clinical) Antibody business 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis Journal. 13:208-214 |
| ISSN: | 1477-0970 1352-4585 |
| DOI: | 10.1177/1352458506070762 |
| Popis: | Development of neutralizing antibodies (NAbs) reduces the clinical efficacy of interferon beta (IFNβ) treatment in multiple sclerosis (MS) patients. The aim of this study was to evaluate NAb seroprevalence (frequency of patients with NAbs) and immunogenicity (titer levels) of IFNβ preparations in a clinical setting. We analysed 1115 consecutive MS patients, treated with one of the three available IFNβ preparations, for an average of 40 months (1 – 120 months), for the presence of NAbs with the MxA protein induction assay. Overall, 32% of patients were positive for NAbs with neutralizing titers above 10. The frequency of NAbs, ie, the seroprevalence, was 13% in Avonex-treated patients, 43% for Betaferon, 39% for Rebif22 and 30% for Rebif44. In addition, the potential to induce high titer levels, ie, the immunogenicity, was observed to differ between preparations. Avonex, showing the lowest seroprevalence, also showed low immunogenicity and typically induced low titers. Betaferon, showing the highest seroprevalence when inducing NAbs, induced lower titers compared to Rebif22 and Rebif44. Treatment duration over five years only marginally correlated with decreased seroprevalence and titer levels. In conclusion, NAbs to IFNβ are common in a clinical setting and the IFNβ preparations differ not only in NAb seroprevalence, but also in immunogenicity. Multiple Sclerosis 2007; 13: 208–214. http://msj.sagepub.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|